StreetInsider.com News Articles

Form 8-K PRECISION BIOSCIENCES For: May 27

Wed, 27 May 2026 07:30:00 -0400

si-local-file:///var/storage/secattach/20260527/26553531.html

Form 8-K PRECISION BIOSCIENCES For: May 27

Wed, 27 May 2026 07:30:00 -0400

si-local-file:///var/storage/secattach/20260527/26553531.html

Precision BioSciences reports hepatitis B gene therapy data from clinical trial

Wed, 27 May 2026 04:05:42 -0400

Precision BioSciences Inc. (NASDAQ: DTIL) announced clinical trial data showing its experimental hepatitis B treatment PBGENE-HBV eliminated viral DNA in liver tissue and achieved complete loss of a key biomarker in all treated patients.

The data was presented at the European Association for the Study of the Liver Congress. According to the company, liver biopsy analysis demonstrated a 10-fold reduction in covalently closed circular DNA (cccDNA) transcripts after two doses of PBGENE-HBV at 0.4 mg/kg. The treatment also inactivated remaining viral DNA through genetic modifications.

In the ELIMINATE-B study, 38 doses were administered to 16 patients across five treatment groups as of

Precision BioSciences reports hepatitis B gene therapy data from clinical trial

Wed, 27 May 2026 04:05:42 -0400

In the ELIMINATE-B study, 38 doses were administered to 16 patients across five treatment groups as of

Precision BioSciences Announces New and Late-Breaking PBGENE-HBV Clinical Data from the ELIMINATE-B Study at European Association for the Study of the Liver Congress 2026

Wed, 27 May 2026 02:30:00 -0400

- New biopsy data demonstrate that PBGENE-HBV directly eliminated cccDNA through its primary mechanism leading to a 1-log (10-fold) reduction in cccDNA-derived transcripts -

- In the <1% of cccDNA remaining, PBGENE-HBV indels permanently inactivated viral replication by knocking out polymerase function -

- pgRNA established as the biomarker to directly reflect cccDNA elimination by PBGENE-HBV -

- New clinical data demonstrate that PGENE-HBV achieved pgRNA loss in 100% of patients with detectable pgRNA at baseline -

- PBGENE-HBV has a clear therapeutic window with a well-characterized and manageable safety profile across multiple dosing cohorts -

- Investor webcast

Precision BioSciences Announces New and Late-Breaking PBGENE-HBV Clinical Data from the ELIMINATE-B Study at European Association for the Study of the Liver Congress 2026

Wed, 27 May 2026 02:30:00 -0400

- New biopsy data demonstrate that PBGENE-HBV directly eliminated cccDNA through its primary mechanism leading to a 1-log (10-fold) reduction in cccDNA-derived transcripts -
- In the <1% of cccDNA remaining, PBGENE-HBV indels permanently inactivated viral replication by knocking out polymerase function -
- pgRNA established as the biomarker to directly reflect cccDNA elimination by PBGENE-HBV -
- New clinical data demonstrate that PGENE-HBV achieved pgRNA loss in 100% of patients with detectable pgRNA at baseline -
- PBGENE-HBV has a clear therapeutic window with a well-characterized and manageable safety profile across multiple dosing cohorts -
- Investor webcast

Precision BioSciences Announces New and Late-Breaking PBGENE-HBV Clinical Data from the ELIMINATE-B Study at European Association for the Study of the Liver Congress 2026

Wed, 27 May 2026 02:30:00 -0400

- New biopsy data demonstrate that PBGENE-HBV directly eliminated cccDNA through its primary mechanism leading to a 1-log (10-fold) reduction in cccDNA-derived transcripts -
- In the <1% of cccDNA remaining, PBGENE-HBV indels permanently inactivated viral replication by knocking out polymerase function -
- pgRNA established as the biomarker to directly reflect cccDNA elimination by PBGENE-HBV -
- New clinical data demonstrate that PGENE-HBV achieved pgRNA loss in 100% of patients with detectable pgRNA at baseline -
- PBGENE-HBV has a clear therapeutic window with a well-characterized and manageable safety profile across multiple dosing cohorts -
- Investor webcast

Precision BioSciences Announces New and Late-Breaking PBGENE-HBV Clinical Data from the ELIMINATE-B Study at European Association for the Study of the Liver Congress 2026

Wed, 27 May 2026 02:30:00 -0400

- New biopsy data demonstrate that PBGENE-HBV directly eliminated cccDNA through its primary mechanism leading to a 1-log (10-fold) reduction in cccDNA-derived transcripts -
- In the <1% of cccDNA remaining, PBGENE-HBV indels permanently inactivated viral replication by knocking out polymerase function -
- pgRNA established as the biomarker to directly reflect cccDNA elimination by PBGENE-HBV -
- New clinical data demonstrate that PGENE-HBV achieved pgRNA loss in 100% of patients with detectable pgRNA at baseline -
- PBGENE-HBV has a clear therapeutic window with a well-characterized and manageable safety profile across multiple dosing cohorts -
- Investor webcast

Precision BioSciences Announces New and Late-Breaking PBGENE-HBV Clinical Data from the ELIMINATE-B Study at European Association for the Study of the Liver Congress 2026

Wed, 27 May 2026 02:30:00 -0400

- New biopsy data demonstrate that PBGENE-HBV directly eliminated cccDNA through its primary mechanism leading to a 1-log (10-fold) reduction in cccDNA-derived transcripts -
- In the <1% of cccDNA remaining, PBGENE-HBV indels permanently inactivated viral replication by knocking out polymerase function -
- pgRNA established as the biomarker to directly reflect cccDNA elimination by PBGENE-HBV -
- New clinical data demonstrate that PGENE-HBV achieved pgRNA loss in 100% of patients with detectable pgRNA at baseline -
- PBGENE-HBV has a clear therapeutic window with a well-characterized and manageable safety profile across multiple dosing cohorts -
- Investor webcast

Precision BioSciences Announces New and Late-Breaking PBGENE-HBV Clinical Data from the ELIMINATE-B Study at European Association for the Study of the Liver Congress 2026

Wed, 27 May 2026 02:30:00 -0400

- New biopsy data demonstrate that PBGENE-HBV directly eliminated cccDNA through its primary mechanism leading to a 1-log (10-fold) reduction in cccDNA-derived transcripts -
- In the <1% of cccDNA remaining, PBGENE-HBV indels permanently inactivated viral replication by knocking out polymerase function -
- pgRNA established as the biomarker to directly reflect cccDNA elimination by PBGENE-HBV -
- New clinical data demonstrate that PGENE-HBV achieved pgRNA loss in 100% of patients with detectable pgRNA at baseline -
- PBGENE-HBV has a clear therapeutic window with a well-characterized and manageable safety profile across multiple dosing cohorts -
- Investor webcast

Precision BioSciences Announces New and Late-Breaking PBGENE-HBV Clinical Data from the ELIMINATE-B Study at European Association for the Study of the Liver Congress 2026

Wed, 27 May 2026 02:30:00 -0400

- New biopsy data demonstrate that PBGENE-HBV directly eliminated cccDNA through its primary mechanism leading to a 1-log (10-fold) reduction in cccDNA-derived transcripts -
- In the <1% of cccDNA remaining, PBGENE-HBV indels permanently inactivated viral replication by knocking out polymerase function -
- pgRNA established as the biomarker to directly reflect cccDNA elimination by PBGENE-HBV -
- New clinical data demonstrate that PGENE-HBV achieved pgRNA loss in 100% of patients with detectable pgRNA at baseline -
- PBGENE-HBV has a clear therapeutic window with a well-characterized and manageable safety profile across multiple dosing cohorts -
- Investor webcast

Precision BioSciences Announces New and Late-Breaking PBGENE-HBV Clinical Data from the ELIMINATE-B Study at European Association for the Study of the Liver Congress 2026

Wed, 27 May 2026 02:30:00 -0400

- New biopsy data demonstrate that PBGENE-HBV directly eliminated cccDNA through its primary mechanism leading to a 1-log (10-fold) reduction in cccDNA-derived transcripts -
- In the <1% of cccDNA remaining, PBGENE-HBV indels permanently inactivated viral replication by knocking out polymerase function -
- pgRNA established as the biomarker to directly reflect cccDNA elimination by PBGENE-HBV -
- New clinical data demonstrate that PGENE-HBV achieved pgRNA loss in 100% of patients with detectable pgRNA at baseline -
- PBGENE-HBV has a clear therapeutic window with a well-characterized and manageable safety profile across multiple dosing cohorts -
- Investor webcast

Precision BioSciences Announces New and Late-Breaking PBGENE-HBV Clinical Data from the ELIMINATE-B Study at European Association for the Study of the Liver Congress 2026

Wed, 27 May 2026 02:30:00 -0400

- New biopsy data demonstrate that PBGENE-HBV directly eliminated cccDNA through its primary mechanism leading to a 1-log (10-fold) reduction in cccDNA-derived transcripts -
- In the <1% of cccDNA remaining, PBGENE-HBV indels permanently inactivated viral replication by knocking out polymerase function -
- pgRNA established as the biomarker to directly reflect cccDNA elimination by PBGENE-HBV -
- New clinical data demonstrate that PGENE-HBV achieved pgRNA loss in 100% of patients with detectable pgRNA at baseline -
- PBGENE-HBV has a clear therapeutic window with a well-characterized and manageable safety profile across multiple dosing cohorts -
- Investor webcast

Precision BioSciences Announces New and Late-Breaking PBGENE-HBV Clinical Data from the ELIMINATE-B Study at European Association for the Study of the Liver Congress 2026

Wed, 27 May 2026 02:30:00 -0400

- New biopsy data demonstrate that PBGENE-HBV directly eliminated cccDNA through its primary mechanism leading to a 1-log (10-fold) reduction in cccDNA-derived transcripts -
- In the <1% of cccDNA remaining, PBGENE-HBV indels permanently inactivated viral replication by knocking out polymerase function -
- pgRNA established as the biomarker to directly reflect cccDNA elimination by PBGENE-HBV -
- New clinical data demonstrate that PGENE-HBV achieved pgRNA loss in 100% of patients with detectable pgRNA at baseline -
- PBGENE-HBV has a clear therapeutic window with a well-characterized and manageable safety profile across multiple dosing cohorts -
- Investor webcast

Precision BioSciences Announces New and Late-Breaking PBGENE-HBV Clinical Data from the ELIMINATE-B Study at European Association for the Study of the Liver Congress 2026

Wed, 27 May 2026 02:30:00 -0400

- New biopsy data demonstrate that PBGENE-HBV directly eliminated cccDNA through its primary mechanism leading to a 1-log (10-fold) reduction in cccDNA-derived transcripts -
- In the <1% of cccDNA remaining, PBGENE-HBV indels permanently inactivated viral replication by knocking out polymerase function -
- pgRNA established as the biomarker to directly reflect cccDNA elimination by PBGENE-HBV -
- New clinical data demonstrate that PGENE-HBV achieved pgRNA loss in 100% of patients with detectable pgRNA at baseline -
- PBGENE-HBV has a clear therapeutic window with a well-characterized and manageable safety profile across multiple dosing cohorts -
- Investor webcast

Precision BioSciences Announces New and Late-Breaking PBGENE-HBV Clinical Data from the ELIMINATE-B Study at European Association for the Study of the Liver Congress 2026

Wed, 27 May 2026 02:30:00 -0400

- New biopsy data demonstrate that PBGENE-HBV directly eliminated cccDNA through its primary mechanism leading to a 1-log (10-fold) reduction in cccDNA-derived transcripts -
- In the <1% of cccDNA remaining, PBGENE-HBV indels permanently inactivated viral replication by knocking out polymerase function -
- pgRNA established as the biomarker to directly reflect cccDNA elimination by PBGENE-HBV -
- New clinical data demonstrate that PGENE-HBV achieved pgRNA loss in 100% of patients with detectable pgRNA at baseline -
- PBGENE-HBV has a clear therapeutic window with a well-characterized and manageable safety profile across multiple dosing cohorts -
- Investor webcast

Form 8-K PRECISION BIOSCIENCES For: May 21

Tue, 26 May 2026 17:20:00 -0400
si-local-file:///var/storage/secattach/20260526/26551322.html

Form 8-K PRECISION BIOSCIENCES For: May 21

Tue, 26 May 2026 17:20:00 -0400
si-local-file:///var/storage/secattach/20260526/26551322.html

Form 4 PRECISION BIOSCIENCES For: May 20 Filed by: Buehler Kevin

Fri, 22 May 2026 07:32:00 -0400
si-local-file:///var/storage/secattach/20260522/26538573.html

Form 4 PRECISION BIOSCIENCES For: May 20 Filed by: Buehler Kevin

Fri, 22 May 2026 07:32:00 -0400
si-local-file:///var/storage/secattach/20260522/26538573.html

Form 4 PRECISION BIOSCIENCES For: May 20 Filed by: Pire Shari Lisa

Fri, 22 May 2026 07:31:00 -0400
si-local-file:///var/storage/secattach/20260522/26538563.html

Form 4 PRECISION BIOSCIENCES For: May 20 Filed by: Pire Shari Lisa

Fri, 22 May 2026 07:31:00 -0400
si-local-file:///var/storage/secattach/20260522/26538563.html

Form 4 PRECISION BIOSCIENCES For: May 20 Filed by: Brown Melinda

Fri, 22 May 2026 07:31:00 -0400
si-local-file:///var/storage/secattach/20260522/26538565.html

Form 4 PRECISION BIOSCIENCES For: May 20 Filed by: Brown Melinda

Fri, 22 May 2026 07:31:00 -0400
si-local-file:///var/storage/secattach/20260522/26538565.html

Form 4 PRECISION BIOSCIENCES For: May 20 Filed by: Frankel Stanley

Fri, 22 May 2026 07:31:00 -0400
si-local-file:///var/storage/secattach/20260522/26538566.html